Beyond Sovaldi: PCSK9 Inhibitor Costs Are Also On PBMs’ Radar
Executive Summary
The cost of the new class of drugs for hard-to-treat cholesterol could have an even bigger impact on the health care system than Sovaldi, executives from CVS Caremark and Express Scripts caution.
You may also be interested in...
Preparing For Battle: PCSK9 Sponsors Stake Their Ground
The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.
Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.
Back To The Well: Rebate Reform Rule Delay Would Fund Senate Gun Control Bill Provisions
For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.